Teva Pharmaceutical Industries has secured broad commercial rights to Polpharma Biologics’ PB018, a proposed biosimilar to Roche’s multiple sclerosis medicine Ocrevus, or ocrelizumab. Under the licensing agreement, Teva will lead regulatory submissions and, subject to approval, commercialize intravenous and subcutaneous formulations across the United States, Europe, Brazil, Canada, Australia, New Zealand, Israel and Turkey.
Polpharma Biologics will remain responsible for developing and manufacturing PB018, creating a division of labour in which the smaller biosimilar specialist carries the scientific and production burden while Teva applies its regulatory infrastructure, payer relationships and multinational commercial reach. Financial terms, including any upfront payment, development milestones, royalties or supply margins, were not disclosed.
The agreement places Teva in a commercially valuable but increasingly contested market. Roche reported 2025 Ocrevus sales of CHF 7.01 billion, up 9% at constant exchange rates, making the medicine its largest pharmaceutical product by annual revenue. That scale explains the attraction, but it also means that PB018 will have to navigate an unusually competitive development, patent, contracting and launch environment before it can generate meaningful revenue.
Why is Teva licensing PB018 while the Ocrevus biosimilar remains at an early clinical stage?
PB018 is not a near-market asset. Polpharma Biologics is preparing a randomized, double-blind clinical pharmacology study expected to begin in October 2026, placing the programme several years away from any plausible commercial launch. Teva is therefore buying strategic positioning rather than an immediate revenue contribution.
The logic fits Teva’s attempt to use biosimilars as a higher-value extension of its generics infrastructure. The company said in June 2026 that it had 11 biosimilars on the market and 13 more in its pipeline across oncology, immunology, ophthalmology and respiratory care. It has also set an objective of generating approximately $800 million in biosimilar revenue during 2027.
PB018 extends that portfolio into a major neurology franchise and gives Teva another asset that could benefit from the company’s existing experience with complex biologics. Recent milestones include the United States approval of its denosumab biosimilar Ponlimsi, regulatory reviews of an omalizumab biosimilar and the European rollout of the aflibercept biosimilar Ahzantive.
The transaction also illustrates how Teva is balancing internal development with partnerships. Developing every biosimilar from cell line selection through global commercialization requires substantial scientific investment, manufacturing capacity and regulatory resources. By licensing a programme for which Polpharma Biologics retains development and manufacturing responsibility, Teva can expand its commercial pipeline without absorbing the entire development organisation.
That structure does not eliminate risk. Teva remains dependent on its partner’s ability to deliver analytical comparability, consistent clinical material, scalable manufacturing and a regulatory-ready data package. Any delay in recruitment, manufacturing validation or comparability work could push the commercial opportunity further into the future.
What does the inclusion of intravenous and subcutaneous formulations add to the commercial opportunity?
Securing rights to both administration routes is one of the more consequential parts of the agreement. Ocrevus was established as an intravenous infusion administered every six months, but Roche has subsequently introduced a subcutaneous formulation intended to reduce the time and infrastructure required for administration.
In the United States, the subcutaneous product is marketed as Ocrevus Zunovo and contains both ocrelizumab and hyaluronidase. The formulation is designed to allow a large volume of medicine to be delivered under the skin, changing the administration experience from a lengthy infusion to a substantially shorter healthcare visit.
For a future biosimilar supplier, covering both formulations could protect commercial relevance as the market evolves. A company launching only an intravenous biosimilar may enter a segment that is gradually losing some patients to the more convenient subcutaneous option. Rights to both routes give Teva an opportunity to compete across the franchise rather than within only its original presentation.
The subcutaneous route nevertheless adds regulatory and technical complexity. PB018’s initial announced clinical study focuses on an ocrelizumab biosimilar comparison, while the United States subcutaneous reference product is a multiple-ingredient formulation containing hyaluronidase. Development will therefore require more than simply transferring the intravenous biosimilar into a different container.
Formulation characteristics, pharmacokinetic bridging, immunogenicity, injection reactions, combination-product requirements and manufacturing controls may all influence the eventual regulatory strategy. Teva and Polpharma Biologics have not disclosed how the subcutaneous programme will be sequenced or what additional studies may be required.
This matters commercially because administration convenience has become an important defence strategy for originator biologic manufacturers. By moving established patients toward a newer formulation before biosimilars arrive, an originator can preserve parts of the franchise even after competition begins against the original intravenous medicine.
Can the planned PB018 study provide the evidence needed to advance a credible biosimilar application?
The proposed Phase 1 study is expected to enrol approximately 222 adults with multiple sclerosis. Participants will be randomized to receive PB018, United States-licensed Ocrevus or European Union-approved Ocrevus in a double-blind, parallel-group design.
Its primary purpose is to demonstrate pharmacokinetic similarity. The study is also expected to examine pharmacodynamics, including B-cell depletion, alongside safety, immunogenicity and magnetic resonance imaging measures over a 24-week treatment period.
This design reflects the central principle of biosimilar development. The objective is not to prove from the beginning that ocrelizumab works in multiple sclerosis, because the reference medicine’s clinical benefit is already established. The development programme instead has to demonstrate that PB018 is highly similar to the reference product and that any observed differences are not clinically meaningful.
Using both United States and European reference products is commercially important because Teva intends to seek approvals across multiple regulatory regions. A successful three-way comparison could help establish the scientific bridge required to use a common development package in several markets.
However, a biosimilar programme cannot be judged on pharmacokinetic results alone. Analytical similarity, structural characterization, biological activity, process consistency and immunogenicity will carry substantial weight. Regulators will also examine whether the commercial manufacturing process produces material that remains comparable to the batches used during clinical development.
The announced October 2026 start date creates another execution test. Recruiting patients for a biosimilar study in a therapeutic area with several established disease-modifying treatments can be challenging. Participants and investigators may have limited motivation to enter a comparability study when the reference medicine is already available, particularly in well-reimbursed markets.
How crowded could the ocrelizumab biosimilar market become before PB018 reaches regulators?
PB018 is not entering an empty pipeline. Amgen is developing ABP 692 in a study designed to compare pharmacokinetic similarity with United States and European ocrelizumab. Celltrion is also advancing CT-P53 through a programme comparing its candidate with the reference medicine in relapsing-remitting multiple sclerosis.
Other developers have disclosed ocrelizumab biosimilar ambitions, indicating that the eventual market may include several competitors rather than a single challenger to Roche. This raises the importance of development timing, filing quality, patent strategy, manufacturing readiness and the ability to negotiate payer contracts before rival products secure preferred positions.
Being first is not the only route to biosimilar success, but late entry can reduce pricing power. Early entrants can establish hospital contracts, reimbursement pathways, inventory relationships and clinician familiarity before the market becomes heavily discounted.
Teva’s commercial scale may partly offset a later development timeline. The company already sells complex generic and biosimilar products across many of the territories included in the agreement. That infrastructure can support tender participation, payer negotiations, pharmacovigilance and product distribution.
Polpharma Biologics also brings relevant multiple sclerosis biosimilar experience. Its portfolio includes PB006, a natalizumab biosimilar developed with Sandoz, as well as other monoclonal antibody programmes. Yet success with one biosimilar does not automatically transfer to another, particularly when the target product has different structural, functional and administration requirements.
PB018 will ultimately need a clear competitive proposition beyond being less expensive than Ocrevus. Reliable supply, contracting flexibility and access to both intravenous and subcutaneous presentations may become as important as the scientific comparability package.
Why is Roche’s entrenched Ocrevus position both an opportunity and an obstacle for Teva?
Ocrevus offers the type of reference market that biosimilar developers favour. Its CHF 7.01 billion in 2025 sales provides a large revenue pool from which even a modest market share could become commercially meaningful. The medicine also continued growing, suggesting that the opportunity is not limited to replacing a rapidly declining legacy product.
Its strength is also the central obstacle. Ocrevus has established familiarity among neurologists and is approved for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis. Its six-month dosing schedule has become a recognizable part of treatment planning, while Roche continues to generate clinical data and expand the product’s administration options.
Biosimilar adoption in this setting will depend on more than regulatory approval. Neurologists may be cautious about switching stable patients receiving a long-term immunomodulatory therapy, especially when questions arise about immunogenicity, infusion reactions or differences in delivery.
Payers and healthcare systems may apply stronger pressure when savings are substantial. Infused medicines also operate through procurement and reimbursement models that can give hospitals, clinics and insurers meaningful influence over product selection. In the United States, buy-and-bill economics, rebate arrangements and formulary preferences could determine adoption more quickly than patient-level brand awareness.
The subcutaneous formulation introduces a different workflow calculation. Hospitals may value reduced chair time and nursing resources, but pricing, reimbursement and product acquisition costs will still shape whether the convenience produces genuine system-level savings.
What does the licensing agreement mean for Teva’s stock and investor sentiment?
Teva shares closed at $32.95 on July 10, 2026, the trading session after the licensing announcement. The stock was down approximately 4.9% across the latest five-session comparison and about 1.9% over 30 days, while remaining within a 52-week range of $14.99 to $37.35.
The muted response indicates that investors are not treating PB018 as a near-term financial catalyst. That interpretation is reasonable because the clinical study has not started, financial terms remain undisclosed and any launch is likely years away.
The longer-term market trend has been considerably more constructive, with Teva shares roughly doubling over the preceding 12 months. Investor confidence has been supported by growth from branded products including Austedo, Ajovy and Uzedy, improving profitability expectations and progress within the company’s broader transformation strategy.
PB018 should therefore be viewed as a pipeline option that reinforces Teva’s biosimilar platform rather than as an asset capable of changing near-term earnings forecasts. Its financial importance will increase only after the programme produces convincing comparability data, advances toward regulatory submission and gains greater clarity on launch timing.
The next meaningful milestones are likely to be the start of the PB018 clinical study, confirmation of recruitment progress and further disclosure concerning the subcutaneous development plan. Regulators and investors will also watch whether Polpharma Biologics can establish a manufacturing process suitable for large commercial volumes across multiple jurisdictions.
For Teva, the agreement offers access to one of the pharmaceutical industry’s largest biologic franchises without requiring the company to originate the full programme internally. For Polpharma Biologics, Teva provides the regulatory and commercial reach needed to compete in major markets. The attraction is clear, but the value of the partnership will be decided by clinical execution, manufacturing consistency and whether PB018 can reach the market before the ocrelizumab biosimilar field becomes crowded.
